

Senzime receives approval by Ethics Committee to start clinical trials

The Regional Ethical Review Board (EPN) has granted approval to Senzime AB to conduct a clinical study at Uppsala University Hospital comprising a maximum of 50 patients.

To date, four patients have been monitored using Senzime's sensor technology and the company has previously stated that it will continuously add to its base of clinical data. The study that now has been approved by EPN will give an important and value-added contribution to Senzime's position in this respect.

"In our industry, clinical studies are a key test of any technology and in many cases a prerequisite for approaching major markets. At the same time, they are often very hard to stage for a company of our size. Therefore, we really appreciate the decision taken by the Ethical Review Board. We are excited to learn more about our product offering through these upcoming trials and see this as a very good opportunity to add value to the company", says Staffan Boström, CEO of Senzime.

The Clinical Diagnostics Market

Senzime is offering its unique sensor technology for bedside patient monitoring. Current focus is to launch its instrument for monitoring of patients' blood glucose levels in the operating rooms and the intensive care units. Due to the adoption of tight glyceemic control schemes in these settings, it is becoming more and more crucial for hospitals to have, or put in place continuous monitoring of glucose in whole blood.

US based industry analysts Frost & Sullivan (2005) estimates that 6,000 ICU's in the U.S. manage roughly 55,000 patients per day. Continuous glucose checks on all patients represent a sizeable, and to a fair degree untapped, market opportunity.

Senzime's view is that the company has a competitive offering in this market place.

For more information, please visit www.senzime.com or contact:

Staffan Boström, CEO
Tel. +46 (0)18 51 56 40
Mobile +46 (0)70 607 10 02
staffan.bostrom@senzime.com
www.senzime.com

About Sensime

Uppsala based Sensime, founded in 1999, has developed a biosensor which makes it possible to continuously and automatically monitor critical components in complex biological fluids. The need for such on-line measurements is increasing in a range of industries, for example in pharmaceutical production and health care.

Sensime's product offering consists of a measurement instrument and disposable sensor units, similar to the machine/filter combination one would find in a modern dialysis machine.

In parallel with working in the pharmaceutical production field (bioreactors/fermentation), Sensime is adapting its instrument for automated and continuous monitoring of whole blood glucose at intensive care units. The first patient was monitored by a Sensime instrument in June 2009.

The company's largest owners are members of the Crafoord family, primarily known for its key role in developing Swedish medical device company Gambro.

Sensime is a publicly listed company and its shares trade at Swedish AktieTorget (www.aktietorget.se).